New long‐acting monoclonal antibody reduces RSV infections in healthy preterm infants

2021 ◽  
Vol 57 (4) ◽  
pp. 593-593
Keyword(s):  
Monoclonal Antibody ◽  
Preterm Infants ◽  
Long Acting

P051 QLS-215 IS A LONG-ACTING MONOCLONAL ANTIBODY PLASMA KALLIKREIN INHIBITOR FOR THE POTENTIAL TREATMENT OF HAE

2021 ◽  
Vol 127 (5) ◽  
pp. S28
Author(s):  
P. Bista ◽  
A. Nichols ◽  
T. Kiselak ◽  
P. Harwin ◽  
J. Violin ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Plasma Kallikrein ◽  
Potential Treatment ◽  
Kallikrein Inhibitor ◽  
Long Acting

scholarly journals A Potential Long-Acting LDL-Cholesterol–Lowering PCSK9 Monoclonal Antibody

JACC: Asia ◽  
2021 ◽  
Author(s):  
Yimin Cui ◽  
Xia Zhao ◽  
Litong Qi ◽  
Xin Li ◽  
Zhijun Huang ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Ldl Cholesterol ◽  
Cholesterol Lowering ◽  
Long Acting

scholarly journals ALD1613, A Novel Long-Acting Monoclonal Antibody to Control ACTH-Driven Pharmacology

Endocrinology ◽  
2016 ◽  
pp. en.2016-1455 ◽  
Author(s):  
Andrew L. Feldhaus ◽  
Katie Anderson ◽  
Benjamin Dutzar ◽  
Ethan Ojala ◽  
Patricia Dianne McNeill ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Long Acting

scholarly journals A Case of Severe Asthma with Eosinophilic Otitis Media Successfully Treated with Anti-IgE Monoclonal Antibody Omalizumab

2012 ◽  
Vol 2012 ◽  
pp. 1-5 ◽  
Author(s):  
Azusa Okude ◽  
Etsuko Tagaya ◽  
Mitsuko Kondo ◽  
Manabu Nonaka ◽  
Jun Tamaoki
Keyword(s):  
Monoclonal Antibody ◽  
Hearing Loss ◽  
Medical Treatment ◽  
Otitis Media ◽  
High Dose ◽  
High Dose Corticosteroid ◽  
Oral Steroids ◽  
Dose Corticosteroid ◽  
Long Acting ◽  
Refractory Asthma

A 51-year-old woman had been receiving medical treatment for asthma since she was 21 years old. However, her asthma was poorly controlled despite treatment involving combination inhalation of high-dose corticosteroid and long-actingβ2-aderenergic agonist (LABA) and regularly taking oral steroids. Hearing loss and otorrhea appeared at the age of 44, and she was given a diagnosis of eosinophilic otitis media (EOM) and received medical treatment. In 2007, symptoms of asthma and otitis media deteriorated. In December 2009, omalizumab therapy was started for refractory asthma. After 2 months of omalizumab treatment, not only asthma, but also hearing loss improved. It is suggested that early initiation of omalizumab therapy may inhibit the progression of progressive EOM.

scholarly journals A Phase 1 study of the long‐acting anti‐IL‐5 monoclonal antibody GSK3511294 in patients with asthma

2021 ◽  
Author(s):  
Dave Singh ◽  
Rainard Fuhr ◽  
Nicholas P. Bird ◽  
Sarah Mole ◽  
Kelly Hardes ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Phase 1 ◽  
Phase 1 Study ◽  
Long Acting

PRO 140, a monoclonal antibody targeting CCR5, as a long-acting, single-agent maintenance therapy for HIV-1 infection

2018 ◽  
Vol 19 (3) ◽  
pp. 85-93 ◽  
Author(s):  
Kush Dhody ◽  
Nader Pourhassan ◽  
Kazem Kazempour ◽  
Derry Green ◽  
Shide Badri ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Maintenance Therapy ◽  
Single Agent ◽  
Antibody Targeting ◽  
Long Acting ◽  
Hiv 1

Live vaccines and immunosuppressive monoclonal antibodies: weighing up the benefit–risk assessment for natalizumab

2020 ◽  
Author(s):  
Jean-Marc Schwob ◽  
Caroline F Samer ◽  
Patrice H Lalive ◽  
Gilles A Eperon
Keyword(s):  
Risk Assessment ◽  
Monoclonal Antibody ◽  
Monoclonal Antibodies ◽  
Mode Of Action ◽  
Live Vaccines ◽  
Specific Mode ◽  
Benefit Risk Assessment ◽  
Long Acting ◽  
Case Basis

Highlight We consider the safety of live vaccines when used in patients on natalizumab, a long-acting immunosuppressive monoclonal antibody. Based on this drug’s specific mode of action we propose a benefit/risk assessment on a case-by-case basis with individual considerations, rather than a generic contra-indication.

Safety, Tolerability, and Pharmacokinetics of a Long-Acting Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01LS in HIV-1-Exposed Newborn Infants

2021 ◽  
Author(s):  
Elizabeth J McFarland ◽  
Coleen K Cunningham ◽  
Petronella Muresan ◽  
Edmund V Capparelli ◽  
Charlotte Perlowski ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Half Life ◽  
Newborn Infants ◽  
Adjunct Treatment ◽  
Perinatal Hiv ◽  
Antiretroviral Prophylaxis ◽  
Terminal Half Life ◽  
Local Reactions ◽  
Long Acting ◽  
Hiv 1

Abstract Background Perinatal HIV-1 continues to occur due to barriers to effective antiretroviral prevention that might be mitigated by long-acting broadly neutralizing monoclonal antibodies (bNAbs). Methods Extended half-life bNAb, VRC01LS, was administered subcutaneously (SC) at 80 mg/dose after birth to HIV-1-exposed, non-breastfed (Cohort 1, n=10) and breastfed (Cohort 2, n=11) infants. Cohort 2 received a second dose (100mg) at 12 weeks. All received antiretroviral prophylaxis. VRC01LS levels were compared to VRC01 levels determined in a prior cohort. Results Local reactions (all Grade <2) occurred in 67% and 20% after Dose 1 and Dose 2, respectively. The weight-banded dose (mean 28.8 mg/kg) of VRC01LS administrated SC achieved a mean +SD plasma level of 222.3 + 71.6 mcg/mL by 24 hours and 44.0 + 11.6 mcg/mL at week 12, prior to Dose 2. The pre-established target of > 50 mcg/mL was attained in 95% and 32% at week 8 and 12, respectively. The terminal half-life was 37-41 days. VRC01LS level after one dose was significantly greater (p=<0.002) than after a VRC01 dose (20mg/kg). No infants acquired HIV-1. Conclusions VRC01LS was well tolerated with pharmacokinetics that support further studies of more potent long-acting bNAbs as adjunct treatment with ARVs to prevent infant HIV-1 transmission.

Sign in / Sign up

Export Citation Format

Share Document